Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360657 | 0.82 | HSD11B1 (0.41) | KCNH2PTGS2 | |
| SCHEMBL26123559 | 0.79 | IDO1 (0.48) | IDO1PTGS2 | |
| SCHEMBL26119405 | 0.79 | PTGS2 (0.43) | IDO1KCNH2PTGS2 | |
| SCHEMBL26121332 | 0.78 | MAP4K1 (0.48) | — | |
| SCHEMBL30360598 | 0.78 | MAP4K1 (0.48) | — | |
| SCHEMBL30360602 | 0.77 | JAK2 (0.41) | TNIKPTGS2 | |
| SCHEMBL26516664 | 0.77 | JAK2 (0.41) | TNIKPTGS2 | |
| SCHEMBL30360601 | 0.77 | MAP4K1 (0.47) | FYNPIK3CALRRK2 | |
| SCHEMBL26516557 | 0.77 | MAP4K1 (0.47) | FYNPIK3CALRRK2 | |
| SCHEMBL26121078 | 0.76 | MAP4K1 (0.46) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200015-B1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | MAP4K4 3059/4885MINK1 1197/4885TNIK 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.